{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:53:47Z","timestamp":1791899627605,"version":"4.3.4"},"reference-count":62,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cabotegravir\/rilpivirine (CAB\/RPV) was recently approved by the US Food and Drug Administration (FDA) as the first complete parenteral antiretroviral (ART) regimen for treatment of people living with HIV (PLWH). As a monthly intramuscular (IM) injection, this therapy constitutes a major departure from the traditional paradigm of oral therapy requiring (at least) daily administration that has defined HIV treatment for decades. Composed of a second\u2010generation integrase inhibitor (INSTI) and nonnucleoside reverse transcriptase inhibitor (NNRTI), CAB\/RPV has achieved high rates of sustained virologic suppression with a favorable safety profile for treatment\u2010experienced PLWH following oral lead\u2010in (OLI) during several clinical trials. In addition to the clinical benefits of this agent, patient\u2010reported outcomes associated with convenience, confidentiality, and the tolerability of the injections have consistently reflected positive perceptions of CAB\/RPV. The novel nature of this therapy in the field of HIV presents logistical challenges. Clinics will need to address barriers related to management of clinic workflow, procurement, reimbursement, and nonadherence. The aim of this review was to summarize the available safety, efficacy, and pharmacokinetic\/pharmacodynamic (PK\/PD) data of this long\u2010acting (LA) injectable regimen as well as discuss some potential considerations for prescribing and operationalization.<\/jats:p>","DOI":"10.1002\/phar.2605","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T15:30:48Z","timestamp":1623771048000},"page":"686-699","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Therapeutic review of cabotegravir\/rilpivirine long\u2010acting antiretroviral injectable and implementation considerations at an HIV specialty clinic"],"prefix":"10.1002","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3957-9753","authenticated-orcid":false,"given":"Zach W.","family":"Howe","sequence":"first","affiliation":[{"name":"Indiana University Health Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Norman","sequence":"additional","affiliation":[{"name":"MedStar Washington Hospital Center Washington District of Columbia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbie F.","family":"Lueken","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice Franciscan Health Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Huesgen","sequence":"additional","affiliation":[{"name":"Indiana University Health Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric K.","family":"Farmer","sequence":"additional","affiliation":[{"name":"Indiana University Health Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Jarrell","sequence":"additional","affiliation":[{"name":"Indiana University Health Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joscelyn E.","family":"Mathis","sequence":"additional","affiliation":[{"name":"Indiana University Health Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle W.","family":"Bonham","sequence":"additional","affiliation":[{"name":"Indiana University Health Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Hahn","sequence":"additional","affiliation":[{"name":"Indiana University Health Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"e_1_2_10_2_1","volume-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"e_1_2_10_3_1","unstructured":"Centers for Disease Control and Prevention.HIV continuum of care US 2014 overall and by age race\/ethnicity transmission route and sex. Updated July 27 2017.www.cdc.gov\/nchhstp\/newsroom\/2017\/HIV\u2010Continuum\u2010of\u2010care.html. Accessed January 31 2021."},{"key":"e_1_2_10_4_1","unstructured":"FDA\u2010approved HIV medicines. Updated Feb 8 2021.https:\/\/hivinfo.nih.gov\/understanding\u2010hiv\/fact\u2010sheets\/fda\u2010approved\u2010hiv\u2010medicines. Accessed February 20 2021."},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0897190005278506"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2017.0009"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-1-200007040-00004"},{"key":"e_1_2_10_8_1","unstructured":"What is \u201cEnding the HIV epidemic: a plan for America\u201d? HIV.gov website. Updated Jan 15 2021.https:\/\/www.hiv.gov\/federal\u2010response\/ending\u2010the\u2010hiv\u2010epidemic\/overview. Accessed January 31 2021."},{"key":"e_1_2_10_9_1","unstructured":"Drug Information: Zidovudine.National Institutes of Health. Updated January 29 2021.https:\/\/aidsinfo.nih.gov\/drugs\/4\/zidovudine\/0\/patient. Accessed February 18 2021."},{"key":"e_1_2_10_10_1","unstructured":"Drug Information: Enfuvirtide.National Institutes of Health. Updated June 12 2020.https:\/\/aidsinfo.nih.gov\/drugs\/306\/enfuvirtide\/0\/patient. Accessed February 18 2021."},{"key":"e_1_2_10_11_1","unstructured":"Drug Information: Ibalizumab\u2010uiyk.National Institutes of Health. Updated Feb 17 2020.https:\/\/aidsinfo.nih.gov\/drugs\/511\/ibalizumab\u2010uiyk\/0\/patient\/. Accessed February 18 2021."},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/eip.12278"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110855"},{"key":"e_1_2_10_14_1","volume-title":"Cabenuva","author":"ViiV Healthcare Inc","year":"2021"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00152-8"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31917-7"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1909512"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904398"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32666-0"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz359.145"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.832"},{"key":"e_1_2_10_22_1","article-title":"Safety and efficacy of cabotegravir + rilpivirine long\u2010acting with and without oral OLI: FLAIR week 124 results","author":"D\u2019Amico R","year":"2020","journal-title":"Glasgow"},{"key":"e_1_2_10_23_1","article-title":"Indirect comparison of 48\u2010week efficacy and safety of long\u2010acting cabotegravir and rilpivirine maintenance very 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV\u20101\u2010infection","author":"Chounta V","year":"2020","journal-title":"Res Sq"},{"key":"e_1_2_10_24_1","unstructured":"ViiV Healthcare.A study to evaluate efficacy and safety of cabotegravir (CAB) long acting (LA) plus (+) rilpivirine (RPV) LA versus Biktarvy\u00ae(BIK) in participants with Human Immunodeficiency Virus (HIV)\u20101 who are virologically suppressed (SOLAR). Clinicaltrials.gov. NCT04542070. Posted September 9 2020. Updated January 27 2021."},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.1207"},{"issue":"1","key":"e_1_2_10_26_1","first-page":"S543","article-title":"Long\u2010term patient adherence and management of treatment interruptions with long\u2010acting injectable cabotegravir + rilpivirine for maintenance therapy in phase 2B\/3 studies","volume":"7","author":"Teichner P","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz359.043"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa515.1905"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.1223"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190487"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz360.2177"},{"key":"e_1_2_10_32_1","unstructured":"ChountaV OvertonET MillsA et al.Patient\u2010reported outcomes through week 48 of ATLAS\u20102M: a study of long\u2010acting cabotegravir and rilpivirine administered every four or eight weeks. 23rd International AIDS Conference. Abstract PEB0261"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-020-02929-8"},{"issue":"1","key":"e_1_2_10_34_1","first-page":"1035","article-title":"Patient\u2010reported outcomes on long\u2010acting cabotegravir\u00a0+\u00a0rilpivirine as maintenance therapy: FLAIR 96\u2010week results","volume":"7","author":"Chounta V","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/25787489.2019.1661696"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002466"},{"key":"e_1_2_10_37_1","unstructured":"Edurant [package insert].Tibotec Pharmaceuticals;2011."},{"key":"e_1_2_10_38_1","unstructured":"MascoliniM.Oral cabotegravir and rilpivirine is durable for 5.5 years in LATTE study. Published Oct 18 2019.https:\/\/i\u2010base.info\/htb\/36702. Accessed February 21 2021."},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25484"},{"key":"e_1_2_10_40_1","unstructured":"WeldED ShaikJS EdickS et al.Distribution of long\u2010acting (LA) cabotegravir (CAB) in plasma mucosal tissues and associated fluids after a single ultrasound\u2010guided intramuscular injection in healthy adult participants. HIV R4P.2021.https:\/\/www.natap.org\/2021\/HIVR4P\/HIVR4P_16.htm. Accessed February 21 2021."},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct1405-192"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz141"},{"key":"e_1_2_10_43_1","unstructured":"JeffreyJ St ClairM WangP et al.HIV A1 or B do not differentially impact cabotegravirin vitropotency or durability. Conference on Retroviruses and Opportunistic Infections. Abstract 532."},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30647-9"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01717-19"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz504"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz360.1396"},{"key":"e_1_2_10_48_1","article-title":"Cabotegravir and rilpivirine PK following long\u2010acting HIV treatment discontinuation","author":"Ford SL","year":"2020","journal-title":"CROI"},{"key":"e_1_2_10_49_1","unstructured":"Vocabria [package insert].ViiV Healthcare Inc;2021."},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw053"},{"issue":"1","key":"e_1_2_10_51_1","doi-asserted-by":"crossref","first-page":"e00487\u201017","DOI":"10.1128\/AAC.00487-17","article-title":"Effect of rifampin on the single\u2010dose pharmacokinetics of oral cabotegravir in healthy subjects","volume":"61","author":"Ford SL","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy726"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz360.2173"},{"key":"e_1_2_10_54_1","unstructured":"ViiV Healthcare.More options for children and adolescents (MOCHA): oral and long\u2010acting injectable cabotegravir and rilpivirine in HIV\u2010infected children and adolescents (MOCHA). Clinicaltrials.gov. NCT03497676. Posted April 13 2018. Updated August 25 2020."},{"key":"e_1_2_10_55_1","article-title":"Cabotegravir pharmacokinetic tail in pregnancy and neonatal outcomes","author":"Patel P","year":"2020","journal-title":"CROI"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002637"},{"key":"e_1_2_10_57_1","unstructured":"CzarnogorskiM D\u2019AmicoR BennP et al.Summary of COVID\u2010related impact on cabotegravir and rilpivirine long\u2010acting (CAB + RPV LA) dosing across the six ongoing global phase IIB and III clinical trials. ID Week 2020.https:\/\/www.natap.org\/2020\/IDWeek\/IDWeek_39.htm. Accessed February 21 2021."},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1080\/25787489.2020.1824718"},{"key":"e_1_2_10_59_1","unstructured":"CzarnogorskiM GarrisC WannamakerP et al.Perceived implementation barriers decrease during initial stages of an implementation science hybrid III study (CUSTOMIZE) of cabotegravir and rilpivirine long\u2010acting (CAB + RPV LA) in US healthcare settings: healthcare team perspective. 23rd International AIDS Conference. Abstract LBPEE42."},{"issue":"3","key":"e_1_2_10_60_1","first-page":"13","article-title":"Connecting patients with specialty products: Part 2: the future of specialty drug distribution","volume":"9","author":"McCain J","year":"2012","journal-title":"Biotechnol Healthc"},{"key":"e_1_2_10_61_1","unstructured":"Buy Bill or Bag? Considerations for Specialty Drug Acquisition | Newsroom \u2013 Vizient. Newsroom.vizientinc.com. March 19 2019.https:\/\/newsroom.vizientinc.com\/buy\u2010bill\u2010or\u2010bag\u2010considerations\u2010for\u2010specialty\u2010drug\u2010acquisition.htm. Accessed January 29 2021."},{"key":"e_1_2_10_62_1","unstructured":"ViiV Healthcare.The LATITUDE study: long\u2010acting therapy to improve treatment success in daily life. Clinicaltrials.gov. NCT03635788. Posted August 17 2018. Updated July 28 2020."},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2018.1511346"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2605","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2605","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:07:50Z","timestamp":1761066470000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":62,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1002\/phar.2605"],"URL":"https:\/\/doi.org\/10.1002\/phar.2605","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"assertion":[{"value":"2021-02-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}